Drug intelligence / Profile preview

loxoprofen sodium + methocarbamol

Development stage
Unknown
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

loxoprofen sodium + methocarbamol is an oral fixed-dose combination drug used for relief of acute musculoskeletal pain and spasms. **Loxoprofen sodium** is a nonsteroidal anti-inflammatory drug (NSAID) that acts as an analgesic and anti-inflammatory agent by non-selectively inhibiting cyclooxygenase (COX) enzymes, thus reducing prostaglandin synthesis. **Methocarbamol** is a centrally acting skeletal muscle relaxant that provides relief from muscle spasms and pain, likely by depressing nerve transmission in the spinal cord, though its exact mechanism is not fully understood. The two drugs act additively without pharmacokinetic interaction, independently providing pain relief and muscle relaxation. This fixed-dose combination is primarily used for acute painful musculoskeletal conditions such as back pain, especially after trauma or strain, and is administered orally in film-coated tablet form[3][1]. The combination has been marketed and trialed as a fixed dose product in Japan and possibly other regions.

02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on loxoprofen sodium + methocarbamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on loxoprofen sodium + methocarbamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call